These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 19318477)

  • 1. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
    Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
    Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
    Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
    J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
    Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
    J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
    Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
    Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
    Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.
    Jäger E; Maeurer M; Höhn H; Karbach J; Jäger D; Zidianakis Z; Bakhshandeh-Bath A; Orth J; Neukirch C; Necker A; Reichert TE; Knuth A
    Int J Cancer; 2000 May; 86(4):538-47. PubMed ID: 10797269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response.
    Tsomides TJ; Reilly EB; Eisen HN
    Int Immunol; 1997 Feb; 9(2):327-38. PubMed ID: 9040014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
    Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S
    J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy).
    Bakacs T; Mehrishi JN; Szabó M; Moss RW
    Pharmacol Res; 2012 Aug; 66(2):192-7. PubMed ID: 22503629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
    Maczek C; Berger TG; Schuler-Thurner B; Schultz ES; Hamann A; Dunbar PR; Cerundolo V; Steinkasserer A; Schuler G
    Int J Cancer; 2005 Jun; 115(3):450-5. PubMed ID: 15688371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.
    Khammari A; Labarrière N; Vignard V; Nguyen JM; Pandolfino MC; Knol AC; Quéreux G; Saiagh S; Brocard A; Jotereau F; Dreno B
    J Invest Dermatol; 2009 Dec; 129(12):2835-42. PubMed ID: 19554023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.
    Dunbar PR; Smith CL; Chao D; Salio M; Shepherd D; Mirza F; Lipp M; Lanzavecchia A; Sallusto F; Evans A; Russell-Jones R; Harris AL; Cerundolo V
    J Immunol; 2000 Dec; 165(11):6644-52. PubMed ID: 11086110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes.
    Adamina M; Bolli M; Albo F; Cavazza A; Zajac P; Padovan E; Schumacher R; Reschner A; Feder C; Marti WR; Oertli D; Heberer M; Spagnoli GC
    Br J Cancer; 2004 Jan; 90(1):263-9. PubMed ID: 14710238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
    Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
    Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.